Edward D. Nudelman
Cancer Biochemist
Seattle, WA
Profile
Noted scientist and innovator in the field of cancer biochemistry and immunology, with 79 papers in top-tier cancer and biochemical journals relating to structure and function of cancer cells, immuno-targeting, and mechanism of action of various disease processes. Among the first to characterize targets for monoclonal antibodies, with papers describing precise epitopes on binding of key monoclonal antibodies to known immunological sites on cells. Founded LipoMed Corp. in 1994, developing pro-angiogenic factors for wound-healing and vascular disease. In an IP Acquisition, merged LipoMed with a leading Seattle Biotech, Cell Therapeutics, in 1994, becoming head scientist and group leader for this Seattle biotech company, remaining as chief scientist until 2004. Founded Lipidomics, Inc., in 2004, investigating the role of oxidized lipids in cardiovascular disease. First to identify antigen-specific epitope for Burkitt’s Lymphoma (Science, 1983) and ligand for E-Selectin (Science, 1990), also known as CD62 antigen-like family member E (CD62E), a key pathway in inflammation and immunology, endothelial-leukocyte adhesion molecule 1 (ELAM-1). Over thirty years experience in Pharma drug research and development, including ten years at Cell Therapeutics in Seattle, WA, receiving “Scientist of the Year,” in 1998. Program Head, Zymequest Corporation, 2005-9, exploring biochemical basis and research and development of synthetic blood technology. Co-founded Glycozym in 2009, an innovative biotech company working on a single blood test for the detection of cancer, which was later acquired by GoTherapeutics, which is very active in research and development of therapeutics in many disease applications. Currently free-lance consultant, advisor viz startups, scientific intellectual property, vetting.
RESEARCH CITATION STATS (as of Oct/2025):
Citations: 8,833
RG Score: 3738
Research Interest Percentile: 99% of all Research Gate members
AWARDS/OWNERSHIPS
Fuji Prize, 1991. Otsuka Pharm (The Biomembrane Institue). “In acknowledgement of a Devotional and Distinguished Contribution,” Outstanding Scientist of the Year.
Scientist of the Year, 1998. The E. Donnall Thomas Award, 1998. Cell Therapeutics Inc. “For Achievements in Science and Technology.”
Rainier Award, 1998. Cell Therapeutics Inc., Humanitarian Award for Community Service.
Co-founder and Head Scientist. The Biomembrane Institute, 1986-1994
------------
SCIENTIFIC PUBLICATIONS (chronologically displayed, 72 papers)
1. Sen-itiroh Hakomori and tumor-associated glycosphingolipids: an astoundingly productive decade, 1980-1990.
Nudelman E.
Glycoconj J. 2021 Dec;38(6):709-715. doi: 10.1007/s10719-021-10026-8. Epub 2021 Nov 26.
2. Professor Sen-itiroh Hakomori (1929-2020): A tribute to a remarkable glycobiologist, mentor and friend!
Laine RA, Gahmberg CG, Sekiguchi K, Kannagi R, Anderson SD, Nudelman ED, Clausen H.
Glycobiology. 2021 Jul;31(7):708-712. doi: 10.1093/glycob/cwab006. Published online 2021 Jan 28.
3. Obituary: Steven Bruce Levery (1949-2014).
Clausen H, Nudelman E, Hakomori S.
Glycoconj J. 2014 Jul;31(5):339-340. doi: 10.1007/s10719-014-9531-0.
4. Identification of a GH110 subfamily of alpha 1,3-galactosidases: novel enzymes for removal of the alpha 3Gal xenotransplantation antigen.
Liu QP, Yuan H, Bennett EP, Levery SB, Nudelman E, Spence J, Pietz G, Saunders K, White T, Olsson ML, Henrissat B, Sulzenbacher G, Clausen H.
J Biol Chem. 2008 Mar 28;283(13):8545-54. doi: 10.1074/jbc.M709020200. Epub 2008 Jan 28.
5. Bacterial glycosidases for the production of universal red blood cells.
Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, Saunders K, Spence J, Nudelman E, Levery SB, White T, Neveu JM, Lane WS, Bourne Y, Olsson ML, Henrissat B, Clausen H.
Nat Biotechnol. 2007 Apr;25(4):454-64. Epub 2007 Apr 1.
6. Metabolism of poly-L-glutamic acid (PG)-paclitaxel (CT-2103); characterization of metabolites generated through proteolysis by lysosomal Cathepsin B and other cysteine proteases.
Shaffer S, Lee CB, Nudelman E, Kumar A, Coon M, Stone I, et al.
2002. [Conference/abstract citation as preserved in the existing CV; venue not specified there.]
7. Intracellular activity of lysophosphatidic acid acyltransferase.
Hollenback D, Nudelman E, Romero L, Bonham L, White T.
Keystone Symposium. 2002; abstract 124. Taos, NM.
8. In vivo identification of monoglutamyl paclitaxel metabolite from poly-L-glutamic acid-paclitaxel (CT-2103) in tumor bearing mice.
Shaffer S, Baker Lee C, de Vries P, Bellamy G, Heasley E, Stone I, et al.
Proceedings of the 49th ASMS Conference on Mass Spectrometry and Allied Topics. 2001; A010970.
9. Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines.
Finney RE, Nudelman E, White T, Bursten S, Klein P, Leer LL, Wang N, Waggoner D, Singer JW, Lewis RA.
Cancer Res. 2000 Sep 15;60(18):5204-13.
10. Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids.
Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E.
J Pharmacol Exp Ther. 1998 Jan;284(1):337-45.
11. High-resolution separation and quantification of neutral lipid and phospholipid species in mammalian cells and sera by multi-one-dimensional thin-layer chromatography.
White T, Bursten S, Federighi D, Lewis RA, Nudelman E.
Anal Biochem. 1998 Apr 10;258(1):109-17.
12. Isolation and expression of an isoform of human CDP-diacylglycerol synthase cDNA.
Weeks R, Dowhan W, Shen H, Balantac N, Meengs B, Nudelman E, Leung DW.
DNA Cell Biol. 1997 Mar;16(3):281-9.
13. Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells.
West J, Tompkins CK, Balantac N, Nudelman E, Meengs B, White T, Bursten S, Coleman J, Kumar A, Singer JW, Leung DW.
DNA Cell Biol. 1997 Jun;16(6):691-701.
14. Synthesis of plasmalopsychosines A and B two novel lysosphingolipids found in human brain.
Sadozai KK, Anand JK, Nudelman ED, Hakomori S.
Carbohydr Res. 1993 Mar 17;241:301-7.
15. Different binding properties of three monoclonal antibodies to sialyl Le(x) glycolipids in a gastric cancer cell line and normal stomach tissue.
Dohi T, Nemoto T, Ohta S, Shitara K, Hanai N, Nudelman E, Hakomori S, Oshima M.
Anticancer Res. 1993 Sep-Oct;13(5A):1277-82.
16. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.
Abdel-Wahab Z, Li WP, Darrow T, Nudelman ED, Towell A, Seigler HF.
Melanoma Res. 1993 Dec;3(6):415-23.
17. Expression of sialylated Lewis(x) antigen in chronic and neoplastic liver diseases.
Jagirdar J, Thung SN, Shah KD, Nudelman E, Singhal A, Paronetto F.
Arch Pathol Lab Med. 1992 Jun;116(6):643-8.
18. Plasmalopsychosine, a novel plasmal (fatty aldehyde) conjugate of psychosine with cyclic acetal linkage. Isolation and characterization from human brain white matter.
Nudelman ED, Levery SB, Igarashi Y, Hakomori S.
J Biol Chem. 1992 Jun 5;267(16):11007-16.
19. Novel modification of glycosphingolipids by long-chain cyclic acetals: isolation and characterization of plasmalocerebroside from human brain.
Levery SB, Nudelman ED, Hakomori S.
Biochemistry. 1992 Jun 16;31(23):5335-40.
20. Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status.
Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE.
J Clin Invest. 1992 Sep;90(3):965-72.
21. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y, et al.
Cancer Res. 1991 Apr 15;51(8):2199-204.
22. Metastatic behavior and cell surface properties of HT-29 human colon carcinoma variant cells selected for their differential expression of sialyl-dimeric Le(x)-antigen.
Matsushita Y, Hoff SD, Nudelman ED, Otaka M, Hakomori S, Ota DM, Cleary KR, Irimura T.
Clin Exp Metastasis. 1991 May-Jun;9(3):283-99.
23. Extended type 1 chain glycosphingolipids: dimeric Lea (III4V4Fuc2Lc6) as human tumor-associated antigen.
Stroud MR, Levery SB, Nudelman ED, Salyan ME, Towell JA, Roberts CE, Watanabe M, Hakomori S.
J Biol Chem. 1991 May 5;266(13):8439-46.
24. CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same carbohydrate ligand, sialyl-Lewis x.
Polley MJ, Phillips ML, Wayner E, Nudelman E, Singhal AK, Hakomori S, Paulson JC.
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6224-8.
25. Characterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes.
Petry K, Greinix HT, Nudelman E, Eisen H, Hakomori S, Levy HL, Reichardt JK.
Biochem Med Metab Biol. 1991 Aug;46(1):93-104.
26. Selectin GMP-140 (CD62; PADGEM) binds to sialosyl-Le(a) and sialosyl-Le(x), and sulfated glycans modulate this binding.
Handa K, Nudelman ED, Stroud MR, Shiozawa T, Hakomori S.
Biochem Biophys Res Commun. 1991 Dec 31;181(3):1223-30.
27. Glycosphingolipids of human myometrium and endometrium and their changes during the menstrual cycle, pregnancy and ageing.
Zhu Z, Deng H, Fenderson BA, Nudelman ED, Tsui Z.
J Reprod Fertil. 1990 Jan;88(1):71-9.
28. Specificity of glycosphingolipid recognition by Entamoeba histolytica trophozoites.
Bailey GB, Nudelman ED, Day DB, Harper CF, Gilmour JR.
Infect Immun. 1990 Jan;58(1):43-7.
29. Use of non-cellular models to study the interaction of E. histolytica with mammalian cells.
Bailey GB, Nudelman ED, Day DB, Gilmour JR, Harper CF.
Arch Invest Med (Mex). 1990;21 Suppl 1:85-9.
30. Profiles of Lewisx-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma.
Singhal AK, Orntoft TF, Nudelman E, Nance S, Schibig L, Stroud MR, Clausen H, Hakomori S.
Cancer Res. 1990 Mar 1;50(5):1375-80.
31. Different patterns of glycolipid antigens are expressed following differentiation of TERA-2 human embryonal carcinoma cells induced by retinoic acid, hexamethylene bisacetamide (HMBA) or bromodeoxyuridine (BUdR).
Andrews PW, Nudelman E, Hakomori S, Fenderson BA.
Differentiation. 1990 Apr;43(2):131-8.
32. Changes in glycolipid expression in human testicular tumor.
Ohyama C, Fukushi Y, Satoh M, Saitoh S, Orikasa S, Nudelman E, Straud M, Hakomori S.
Int J Cancer. 1990 Jun 15;45(6):1040-4.
33. Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen.
Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, Hakomori S, Satoh S.
Anticancer Res. 1990 Nov-Dec;10(6):1579-86.
34. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex.
Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, Paulson JC.
Science. 1990 Nov 23;250(4984):1130-2.
35. Novel tri-and tetrasialosylpoly-N-acetyllactosaminyl gangliosides of human placenta: structure determination of pentadeca- and eicosaglycosylceramides by methylation analysis, fast atom bombardment mass spectrometry, and 1H NMR spectroscopy.
Levery SB, Nudelman ED, Salyan ME, Hakomori S.
Biochemistry. 1989 Sep 19;28(19):7772-81.
36. Human IgG3 monoclonal antibody directed to an unbranched repeating type 2 chain which is highly expressed in colonic and hepatocellular carcinoma.
Miyake M, Kohno N, Nudelman ED, Hakomori S.
Cancer Res. 1989 Oct 15;49(20):5689-95.
37. A series of disialogangliosides with binary 2-3 sialosyllactosamine structure, defined by monoclonal antibody NUH2, are oncodevelopmentally regulated antigens.
Nudelman ED, Mandel U, Levery SB, Kaizu T, Hakomori S.
J Biol Chem. 1989 Nov 5;264(31):18719-25.
38. Antibody 624H12, which detects lung cancer at early stages, recognizes a sugar sequence in the glycosphingolipid difucosylneolactonorhexaosylceramide (V3FucIII3FucnLc6Cer).
Kyogashima M, Mulshine J, Linnoila RI, Jensen S, Magnani JL, Nudelman E, Hakomori S, Ginsburg V.
Arch Biochem Biophys. 1989 Nov 15;275(1):309-14.
39. Human sperm carbohydrate antigens defined by an antisperm human monoclonal antibody derived from an infertile woman bearing antisperm antibodies in her serum.
Tsuji Y, Clausen H, Nudelman E, Kaizu T, Hakomori S, Isojima S.
J Exp Med. 1988 Jul 1;168(1):343-56.
40. 1H-n.m.r. analysis of type-2 chain lacto-gangliosides. Confirmation of structure of a novel cancer-associated fucoganglioside.
Levery SB, Nudelman E, Kannagi R, Symington FW, Andersen NH, Clausen H, Baldwin M, Hakomori S.
Carbohydr Res. 1988 Jul 15;178:121-44.
41. Sulfated lipids represent common antigens on the surface of Trypanosoma cruzi and mammalian tissues.
Petry K, Nudelman E, Eisen H, Hakomori S.
Mol Biochem Parasitol. 1988 Aug;30(2):113-21.
42. A novel tumor-associated, developmentally regulated glycolipid antigen defined by monoclonal antibody ACFH-18.
Nudelman ED, Levery SB, Stroud MR, Salyan ME, Abe K, Hakomori S.
J Biol Chem. 1988 Sep 25;263(27):13942-51.
43. Glycolipid core structure switching from globo- to lacto- and ganglio-series during retinoic acid-induced differentiation of TERA-2-derived human embryonal carcinoma cells.
Fenderson BA, Andrews PW, Nudelman E, Clausen H, Hakomori S.
Dev Biol. 1987 Jul;122(1):21-34.
44. Isolation and characterization of novel glycolipids with blood group A-related structures: galactosyl-A and sialosylgalactosyl-A.
Clausen H, Levery SB, Nudelman ED, Stroud M, Salyan ME, Hakomori S.
J Biol Chem. 1987 Oct 15;262(29):14228-34.
45. Presence of fucolipid antigens with mono- and dimeric X determinant (Lex) in the circulating immune complexes of patients with adenocarcinoma.
Singhal AK, Singhal MC, Nudelman E, Hakomori S, Balint JP, Grant CK, Snyder HW Jr.
Cancer Res. 1987 Nov 1;47(21):5566-71.
46. Novel fucolipids of human adenocarcinoma: disialosyl Lea antigen (III4FucIII6NeuAcIV3NeuAcLc4) of human colonic adenocarcinoma and the monoclonal antibody (FH7) defining this structure.
Nudelman E, Fukushi Y, Levery SB, Higuchi T, Hakomori S.
J Biol Chem. 1986 Apr 25;261(12):5487-95.
47. A novel disialoganglioside (IV3NeuAcIII6NeuAcLc4) of human adenocarcinoma and the monoclonal antibody (FH9) defining this disialosyl structure.
Fukushi Y, Nudelman E, Levery SB, Higuchi T, Hakomori S.
Biochemistry. 1986 May 20;25(10):2859-66.
48. A human monoclonal antibody directed to blood group i antigen: heterohybridoma between human lymphocytes from regional lymph nodes of a lung cancer patient and mouse myeloma.
Hirohashi S, Clausen H, Nudelman E, Inoue H, Shimosato Y, Hakomori S.
J Immunol. 1986 Jun 1;136(11):4163-8.
49. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.
Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT.
J Exp Med. 1986 Jun 1;163(6):1391-404.
50. 1H-n.m.r. analysis of glycolipids possessing mono- and multi-meric X and Y haptens: characterization of two novel extended Y structures from human adenocarcinoma.
Levery SB, Nudelman ED, Andersen NH, Hakomori S.
Carbohydr Res. 1986 Aug 15;151:311-28.
51. Novel fucolipids of human adenocarcinoma: monoclonal antibody specific for trifucosyl Ley (III3FucV3FucVI2FucnLc6) and a possible three-dimensional epitope structure.
Kaizu T, Levery SB, Nudelman E, Stenkamp RE, Hakomori S.
J Biol Chem. 1986 Aug 25;261(24):11254-8.
52. Novel fucolipids of human adenocarcinoma: characterization of the major Ley antigen of human adenocarcinoma as trifucosylnonaosyl Ley glycolipid (III3FucV3FucVI2FucnLc6).
Nudelman E, Levery SB, Kaizu T, Hakomori S.
J Biol Chem. 1986 Aug 25;261(24):11247-53.
53. Further characterization of type 2 and type 3 chain blood group A glycosphingolipids from human erythrocyte membranes.
Clausen H, Levery SB, Nudelman E, Baldwin M, Hakomori S.
Biochemistry. 1986 Nov 4;25(22):7075-85.
54. Repetitive A epitope (type 3 chain A) defined by blood group A1-specific monoclonal antibody TH-1: chemical basis of qualitative A1 and A2 distinction.
Clausen H, Levery SB, Nudelman E, Tsuchiya S, Hakomori S.
Proc Natl Acad Sci U S A. 1985 Feb;82(4):1199-203.
55. Novel fucolipids accumulating in human adenocarcinoma. II. Selective isolation of hybridoma antibodies that differentially recognize mono-, di-, and trifucosylated type 2 chain.
Fukushi Y, Hakomori S, Nudelman E, Cochran N.
J Biol Chem. 1984 Apr 10;259(7):4681-5.
56. Novel fucolipids accumulating in human adenocarcinoma. I. Glycolipids with di- or trifucosylated type 2 chain.
Hakomori S, Nudelman E, Levery SB, Kannagi R.
J Biol Chem. 1984 Apr 10;259(7):4672-80.
57. Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6).
Fukushi Y, Nudelman E, Levery SB, Hakomori S, Rauvala H.
J Biol Chem. 1984 Aug 25;259(16):10511-7.
58. Blood group A glycolipid (Ax) with globo-series structure which is specific for blood group A1 erythrocytes: one of the chemical bases for A1 and A2 distinction.
Clausen H, Watanabe K, Kannagi R, Levery SB, Nudelman E, Arao-Tomono Y, Hakomori S.
Biochem Biophys Res Commun. 1984 Oct 30;124(2):523-9.
59. Characterization of sialosylated Lewisx as a new tumor-associated antigen.
Fukushima K, Hirota M, Terasaki PI, Wakisaka A, Togashi H, Chia D, Suyama N, Fukushi Y, Nudelman E, Hakomori S.
Cancer Res. 1984 Nov;44(11):5279-85.
60. A glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody.
Nudelman E, Kannagi R, Hakomori S, Parsons M, Lipinski M, Wiels J, Fellous M, Tursz T.
Science. 1983 Apr 29;220(4596):509-11.
61. Human cancer-associated gangliosides defined by a monoclonal antibody (IB9) directed to sialosyl alpha 2 leads to 6 galactosyl residue: a preliminary note.
Hakomori S, Nudelman E, Levery SB, Patterson CM.
Biochem Biophys Res Commun. 1983 Jun 29;113(3):791-8.
62. A monoclonal antibody directed to N-acetylneuraminosyl-alpha 2 leads to 6-galactosyl residue in gangliosides and glycoproteins.
Hakomori S, Patterson CM, Nudelman E, Sekiguchi K.
J Biol Chem. 1983 Oct 10;258(19):11819-22.
63. Possible role of ceramide in defining structure and function of membrane glycolipids.
Kannagi R, Nudelman E, Hakomori S.
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3470-4.
64. Monoclonal antibody defining a Burkitt's lymphoma-associated antigen detects carbohydrate on neutral glycolipid.
Lipinski M, Nudelman ED, Wiels J, Parsons M.
J Immunol. 1982 Nov;129(5):2301-4.
65. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.
Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh MY, Hellstrom KE, Hellstrom I.
J Biol Chem. 1982 Nov 10;257(21):12752-6.
66. The common structure in fucosyllactosaminolipids accumulating in human adenocarcinomas, and its possible absence in normal tissue.
Hakomori S, Nudelman E, Kannagi R, Levery SB.
Biochem Biophys Res Commun. 1982 Nov 16;109(1):36-44.
67. A series of human erythrocyte glycosphingolipids reacting to the monoclonal antibody directed to a developmentally regulated antigen SSEA-1.
Kannagi R, Nudelman E, Levery SB, Hakomori S.
J Biol Chem. 1982 Dec 25;257(24):14865-74.
68. The hapten structure of a developmentally regulated glycolipid antigen (SSEA-1) isolated from human erythrocytes and adenocarcinoma: a preliminary note.
Hakomori S, Nudelman E, Levery S, Solter D, Knowles BB.
Biochem Biophys Res Commun. 1981 Jun;100(4):1578-86.
69. A collagen-binding protein on the surface of ejaculated rabbit spermatozoa.
Koehler JK, Nudelman ED, Hakomori S.
J Cell Biol. 1980 Aug;86(2):529-36.
70. Monoclonal antibody directed to the stage-specific embryonic antigen (SSEA-1) reacts with branched glycosphingolipid similar in structure to Ii antigen.
Nudelman E, Hakomori S, Knowles BB, Solter D, Nowinski RC, Tam MR, Young WW Jr.
Biochem Biophys Res Commun. 1980 Nov 28;97(2):443-51.
71. Neutral fucolipids and fucogangliosides of rat hepatoma HTC and H35 cells, rat liver, and hepatocytes.
Baumann H, Nudelman E, Watanabe K, Hakomori S.
Cancer Res. 1979 Jul;39(7 Pt 1):2637-43.
72. Correlation of glycosylation in a membrane protein with a molecular weight of 150,000 with tumorigenic property of rat fibrosarcoma variants.
Koyama K, Nudelman E, Fukuda M, Hakomori S.
Cancer Res. 1979 Sep;39(9):3677-82.
1
|
Liu QP, Yuan H, Bennett EP, Levery SB, Nudelman E, Spence J, Pietz G, Saunders K, White T, Olsson ML, Henrissat B, Sulzenbacher G, Clausen H.
|
J Biol Chem. 2008 Mar 28;283(13):8545-54. doi: 10.1074/jbc.M709020200. Epub 2008 Jan 28.
|
Select item 174013603.
|
2
|
Liu QP, Sulzenbacher G, Yuan H, Bennett EP, Pietz G, Saunders K, Spence J, Nudelman E, Levery SB, White T, Neveu JM, Lane WS, Bourne Y, Olsson ML, Henrissat B, Clausen H.
|
Nat Biotechnol. 2007 Apr;25(4):454-64. Epub 2007 Apr 1.
|
Select item 110166494.
|
3
|
Finney RE, Nudelman E, White T, Bursten S, Klein P, Leer LL, Wang N, Waggoner D, Singer JW, Lewis RA.
|
Cancer Res. 2000 Sep 15;60(18):5204-13.
|
4
|
White T, Bursten S, Federighi D, Lewis RA, Nudelman E.
|
Anal Biochem. 1998 Apr 10;258(1):109-17.
|
5
|
Bursten SL, Federighi D, Wald J, Meengs B, Spickler W, Nudelman E.
|
J Pharmacol Exp Ther. 1998 Jan;284(1):337-45.
|
6
|
West J, Tompkins CK, Balantac N, Nudelman E, Meengs B, White T, Bursten S, Coleman J, Kumar A, Singer JW, Leung DW.
|
DNA Cell Biol. 1997 Jun;16(6):691-701.
|
7
|
Weeks R, Dowhan W, Shen H, Balantac N, Meengs B, Nudelman E, Leung DW.
|
DNA Cell Biol. 1997 Mar;16(3):281-9.
|
8
|
Abdel-Wahab Z, Li WP, Darrow T, Nudelman ED, Towell A, Seigler HF.
|
Melanoma Res. 1993 Dec;3(6):415-23.
|
9
|
Dohi T, Nemoto T, Ohta S, Shitara K, Hanai N, Nudelman E, Hakomori S, Oshima M.
|
Anticancer Res. 1993 Sep-Oct;13(5A):1277-82.
|
10
|
Sadozai KK, Anand JK, Nudelman ED, Hakomori S.
|
Carbohydr Res. 1993 Mar 17;241:301-7. No abstract available.
|
11
|
Stapleton A, Nudelman E, Clausen H, Hakomori S, Stamm WE.
|
J Clin Invest. 1992 Sep;90(3):965-72.
|
12
|
Levery SB, Nudelman ED, Hakomori S.
|
Biochemistry. 1992 Jun 16;31(23):5335-40.
|
13
|
Nudelman ED, Levery SB, Igarashi Y, Hakomori S.
|
J Biol Chem. 1992 Jun 5;267(16):11007-16.
|
14
|
Jagirdar J, Thung SN, Shah KD, Nudelman E, Singhal A, Paronetto F.
|
Arch Pathol Lab Med. 1992 Jun;116(6):643-8.
|
15
|
Handa K, Nudelman ED, Stroud MR, Shiozawa T, Hakomori S.
|
Biochem Biophys Res Commun. 1991 Dec 31;181(3):1223-30.
|
16
|
Petry K, Greinix HT, Nudelman E, Eisen H, Hakomori S, Levy HL, Reichardt JK.
|
Biochem Med Metab Biol. 1991 Aug;46(1):93-104.
|
17
|
Polley MJ, Phillips ML, Wayner E, Nudelman E, Singhal AK, Hakomori S, Paulson JC.
|
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6224-8.
|
18
|
Stroud MR, Levery SB, Nudelman ED, Salyan ME, Towell JA, Roberts CE, Watanabe M, Hakomori S.
|
J Biol Chem. 1991 May 5;266(13):8439-46.
|
19
|
Matsushita Y, Hoff SD, Nudelman ED, Otaka M, Hakomori S, Ota DM, Cleary KR, Irimura T.
|
Clin Exp Metastasis. 1991 May-Jun;9(3):283-99.
|
20
|
Watanabe M, Ohishi T, Kuzuoka M, Nudelman ED, Stroud MR, Kubota T, Kodairo S, Abe O, Hirohashi S, Shimosato Y, et al.
|
Cancer Res. 1991 Apr 15;51(8):2199-204.
|
21
|
Phillips ML, Nudelman E, Gaeta FC, Perez M, Singhal AK, Hakomori S, Paulson JC.
|
Science. 1990 Nov 23;250(4984):1130-2.
|
22
|
Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, Hakomori S, Satoh S.
|
Anticancer Res. 1990 Nov-Dec;10(6):1579-86.
|
23
|
Ohyama C, Fukushi Y, Satoh M, Saitoh S, Orikasa S, Nudelman E, Straud M, Hakomori S.
|
Int J Cancer. 1990 Jun 15;45(6):1040-4.
|
24
|
Andrews PW, Nudelman E, Hakomori S, Fenderson BA.
|
Differentiation. 1990 Apr;43(2):131-8.
|
25
|
Singhal AK, Orntoft TF, Nudelman E, Nance S, Schibig L, Stroud MR, Clausen H, Hakomori S.
|
Cancer Res. 1990 Mar 1;50(5):1375-80.
|
26
|
Bailey GB, Nudelman ED, Day DB, Gilmour JR, Harper CF.
|
Arch Invest Med (Mex). 1990;21 Suppl 1:85-9.
|
27
|
Bailey GB, Nudelman ED, Day DB, Harper CF, Gilmour JR.
|
Infect Immun. 1990 Jan;58(1):43-7.
|
28
|
Zhu Z, Deng H, Fenderson BA, Nudelman ED, Tsui Z.
|
J Reprod Fertil. 1990 Jan;88(1):71-9.
|
29
|
Kyogashima M, Mulshine J, Linnoila RI, Jensen S, Magnani JL, Nudelman E, Hakomori S, Ginsburg V.
|
Arch Biochem Biophys. 1989 Nov 15;275(1):309-14.
|
30
|
Nudelman ED, Mandel U, Levery SB, Kaizu T, Hakomori S.
|
J Biol Chem. 1989 Nov 5;264(31):18719-25.
|
31
|
Miyake M, Kohno N, Nudelman ED, Hakomori S.
|
Cancer Res. 1989 Oct 15;49(20):5689-95.
|
32
|
Levery SB, Nudelman ED, Salyan ME, Hakomori S.
|
Biochemistry. 1989 Sep 19;28(19):7772-81.
|
33
|
Nudelman ED, Levery SB, Stroud MR, Salyan ME, Abe K, Hakomori S.
|
J Biol Chem. 1988 Sep 25;263(27):13942-51.
|
34
|
Petry K, Nudelman E, Eisen H, Hakomori S.
|
Mol Biochem Parasitol. 1988 Aug;30(2):113-21.
|
35
|
Levery SB, Nudelman E, Kannagi R, Symington FW, Andersen NH, Clausen H, Baldwin M, Hakomori S.
|
Carbohydr Res. 1988 Jul 15;178:121-44.
|
36
|
Tsuji Y, Clausen H, Nudelman E, Kaizu T, Hakomori S, Isojima S.
|
J Exp Med. 1988 Jul 1;168(1):343-56.
|
37
|
Singhal AK, Singhal MC, Nudelman E, Hakomori S, Balint JP, Grant CK, Snyder HW Jr.
|
Cancer Res. 1987 Nov 1;47(21):5566-71.
|
38
|
Clausen H, Levery SB, Nudelman ED, Stroud M, Salyan ME, Hakomori S.
|
J Biol Chem. 1987 Oct 15;262(29):14228-34.
|
39
|
Fenderson BA, Andrews PW, Nudelman E, Clausen H, Hakomori S.
|
Dev Biol. 1987 Jul;122(1):21-34.
|
40
|
Clausen H, Levery SB, Nudelman E, Baldwin M, Hakomori S.
|
Biochemistry. 1986 Nov 4;25(22):7075-85.
|
41
|
Nudelman E, Levery SB, Kaizu T, Hakomori S.
|
J Biol Chem. 1986 Aug 25;261(24):11247-53.
|
42
|
Kaizu T, Levery SB, Nudelman E, Stenkamp RE, Hakomori S.
|
J Biol Chem. 1986 Aug 25;261(24):11254-8.
|
44
|
Levery SB, Nudelman ED, Andersen NH, Hakomori S.
|
Carbohydr Res. 1986 Aug 15;151:311-28.
|
45
|
Jacewicz M, Clausen H, Nudelman E, Donohue-Rolfe A, Keusch GT.
|
J Exp Med. 1986 Jun 1;163(6):1391-404.
|
46
|
Hirohashi S, Clausen H, Nudelman E, Inoue H, Shimosato Y, Hakomori S.
|
J Immunol. 1986 Jun 1;136(11):4163-8.
|
47
|
Fukushi Y, Nudelman E, Levery SB, Higuchi T, Hakomori S.
|
Biochemistry. 1986 May 20;25(10):2859-66.
|
48
|
Nudelman E, Fukushi Y, Levery SB, Higuchi T, Hakomori S.
|
J Biol Chem. 1986 Apr 25;261(12):5487-95.
|
49
|
Clausen H, Levery SB, Nudelman E, Tsuchiya S, Hakomori S.
|
Proc Natl Acad Sci U S A. 1985 Feb;82(4):1199-203.
|
50
|
Fukushima K, Hirota M, Terasaki PI, Wakisaka A, Togashi H, Chia D, Suyama N, Fukushi Y, Nudelman E, Hakomori S.
|
Cancer Res. 1984 Nov;44(11):5279-85.
|
51
|
Clausen H, Watanabe K, Kannagi R, Levery SB, Nudelman E, Arao-Tomono Y, Hakomori S.
|
Biochem Biophys Res Commun. 1984 Oct 30;124(2):523-9.
|
52
|
Fukushi Y, Nudelman E, Levery SB, Hakomori S, Rauvala H.
|
J Biol Chem. 1984 Aug 25;259(16):10511-7.
|
53
|
Hakomori S, Nudelman E, Levery SB, Kannagi R.
|
J Biol Chem. 1984 Apr 10;259(7):4672-80.
|
54
|
Fukushi Y, Hakomori S, Nudelman E, Cochran N.
|
J Biol Chem. 1984 Apr 10;259(7):4681-5.
|
55
|
Hakomori S, Patterson CM, Nudelman E, Sekiguchi K.
|
J Biol Chem. 1983 Oct 10;258(19):11819-22.
|
56
|
Hakomori S, Nudelman E, Levery SB, Patterson CM.
|
Biochem Biophys Res Commun. 1983 Jun 29;113(3):791-8.
|
57
|
Nudelman E, Kannagi R, Hakomori S, Parsons M, Lipinski M, Wiels J, Fellous M, Tursz T.
|
Science. 1983 Apr 29;220(4596):509-11.
|
58
|
Kannagi R, Nudelman E, Levery SB, Hakomori S.
|
J Biol Chem. 1982 Dec 25;257(24):14865-74.
|
59
|
Hakomori S, Nudelman E, Kannagi R, Levery SB.
|
Biochem Biophys Res Commun. 1982 Nov 16;109(1):36-44. No abstract available.
|
60
|
Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh MY, Hellström KE, Hellström I.
|
J Biol Chem. 1982 Nov 10;257(21):12752-6.
|
61
|
Lipinski M, Nudelman ED, Wiels J, Parsons M.
|
J Immunol. 1982 Nov;129(5):2301-4.
|
62
|
Kannagi R, Nudelman E, Hakomori S.
|
Proc Natl Acad Sci U S A. 1982 Jun;79(11):3470-4.
|
63
|
Hakomori S, Nudelman E, Levery S, Solter D, Knowles BB.
|
Biochem Biophys Res Commun. 1981 Jun;100(4):1578-86. No abstract available.
|
64
|
Nudelman E, Hakomori S, Knowles BB, Solter D, Nowinski RC, Tam MR, Young WW Jr.
|
Biochem Biophys Res Commun. 1980 Nov 28;97(2):443-51. No abstract available.
|
65
|
Koehler JK, Nudelman ED, Hakomori S.
|
J Cell Biol. 1980 Aug;86(2):529-36.
|
66
|
Koyama K, Nudelman E, Fukuda M, Hakomori S.
|
Cancer Res. 1979 Sep;39(9):3677-82. No abstract available.
|
67
|
Baumann H, Nudelman E, Watanabe K, Hakomori S.
|
Cancer Res. 1979 Jul;39(7 Pt 1):2637-43. 68 Professor Sen-itiroh Hakomori (1929-2020): A tribute to a remarkable glycobiologist, mentor and friend! Roger A. Laine, Carl G. Gahmberg, Kiyotoshi Sekiguchi, Reiji Kannagi, Stephen D. Anderson, Edward D. Nudelman, Henrik Clausen Glycoconj J. 2021 Dec;38(6):709-715. doi: 10.1007/s10719-021-10026-8. Epub 2021 Nov 26. Sen-itiroh Hakomori and tumor-associated glycosphingolipids: an astoundingly productive decade, 1980-1990 69 Edward Nudelman 1 Affiliations expand PMID: 34826038 DOI: 10.1007/s10719-021-10026-8 Molecular and Integrative Biosciences Research Programme Research output: Contribution to journal › Editorial › Scientific 71 Professor Sen-itiroh Hakomori (1929–2020): A tribute to a remarkable glycobiologist, mentor and friend! Roger A Laine, Carl G Gahmberg, Kiyotoshi Sekiguchi, Reiji Kannagi, Stephen D Anderson, Edward D Nudelman, Henrik Clausen Glycobiology, Volume 31, Issue 7, July 2021, Pages 708–712, https://doi.org/10.1093/glycob/cwab006 Published: 28 January 2021 Article history |
US PATENTS
1) 9/87 US Patent 07/094,459 Hakomori, Nudelman, Singhal.
Detection of survived, undegraded carbohydrate epitope
In feces as diagnostic of colon cancer
2) 5/88 US Patent 07/200,160 Hakomori, Nudelman, Levery, et. al.
A novel long-chain glycolipid structure
3) 1/89 US Patent 07/302,890 Nudelman and Clausen.
Monoclonal antibodies directed to tumor-associated antigens
4) 3/89 US Patent 07/320,682 Hakomori, Nudelman and Singhal.
Detection of survived, undegraded carbohydrate epitopes as diagnostic of intestinal disease
5) 4/89 US Patent 07/344,628 Nudelman, Clausen and Hakomori.
Bioorganic synthesis of dimeric Lex
6) 5/91 US Patent 07/695,506 Stroud, Levery, Nudelman.
Extended type 1 chain glycosphingolipids as tumor-associated antigens
7) 11/91 US Patent 07/789,969 Handa, Nudelman and Hakomori.
Identification of carbohydrate epitopes for CD62.
University Experience
1971-1975 University of Washington
B.S., Department of Zoology, honors
1975-1976 University of Washington
B.S., Dept. of Chemistry,(honors)
Research/Professional Experience
2009-Present Head Scientist and Co-Founder,
2005- 2009 Head of Program
Chief Scientist, Lipid Biochemistry
Zymequest Corporation, Beverly, MA
-Head up program involved in the
isolation and characterization of
red blood cell epitopes on all
blood groups responsible for
incompatible crossmatch activity.
-Determined major blood group
incompatibility (H-A) in enzyme
treated rbc’s just prior to clinical
-Produced complex array systems
of molecularly defined carbohydrate
epitopes on human RBCS
1995 – Sept 2005 Chief Scientist, Analytical Lipid Biochemistry, Cell Therapeutics, Inc., Seattle, WA
-Developed proprietary methods for separation,
identification and quantification of virtually every phospholipid and neutral lipid species in
mammalian tissues
-Managed state-of-art analytical lipid lab capable of analyzing high-throughput assays for
quantification of nanomole quantities of lipid species
-Chiefly responsible for identification of
mechanism of action of the company’s lead clinical compound, Apra, a highly effective, novel
chemotherapeutic agent
-Developed novel and state-of-art lipid analytical technology allowing the detection of nanomole
quantities of oxidized lipids in human sera and plasma. Rigourously validated this technology for
the rapid and high-throughput analysis of plasma lipids.
-Developed assay systems for rapid and high throughput screening of discovery compounds using lipid
enzymes and specific radio-labelled substrates. Identified key pathways and mechanism of action
for company’s lead inhibitor for novel cancer target.
-Designed and validated assay system showing reduction of oxidized lipids in in vitro systems with
Company’s lead compounds.
1994 - 1995 Sole Founder, Head Scientist, Lipidomics Corp., Seattle, WA Cancer diagnostics.
1993 - 1994 Sole Founder, Head Scientist, Lipomed Corp., Seattle, WA
-Novel research and development of lipid angiogenic factors isolated from human omentum
-Identification of molecular lipid species causing microvessel growth of human endothelial cells
-In vivo models for angiogenesis
-Proprietary patents written, approved for method of use, pro-angiogenic factors. Sold
technology to CTI (see below)
Oct 86 – Dec 94 Head Scientist and Co-Founder, The Biomembrane Institute, Seattle, WA, with Dr. Hakomori. Led teams through key development of patents, research and development.
-Shigella toxin-binding glycolipids
-Identification and characterization of novel tumor-associated glycolipids
-First elucidation of CD-62 and ELAM-1 receptors as glycolipid antigens
-Novel glycolipids in human brain as nerve cell mitogens
-Uropathogenic E. coli binding to novel glycolipids from vaginal epithelia
1975 - 1986 Staff Scientist, Head Scientist
Fred Hutchinson Cancer Research Center
-Identification of glycolipid as key Burkitt lymphoma-specific tumor associated antigen
-Glycosphingolipid metabolism and
identification in cancer
-Collagen binding proteins on sperm
-Monoclonal antibodies associated with cancer
Jan 78 - Dec 80 Research Associate
Fred Hutchinson Cancer Research Center
-Blood group antigens
-Tumor associated glycosphingolipids
Pharma Specific Experience
DIRECTOR OF ONCOMEMBRANE SEATTLE
3/91- 2/92
Director and chief scientific officer of corporation start-up venture chartered by Otsuka to act as developing arm for patents produced by Biomembrane Institute.
FOUNDER, LIPOMED CORP.
1/93- 3/94
Obtained private capitalization of $700,000 and founded biotechnology company aimed at purifying lipid angiogenic factors from human omentum. Assembled staff of Ph.D.’s and leased research lab space for dedicated biochemical research. Isolated lipid angiogenic factor and submitted patents. Sold technology to Cell Therapeutics (CTI), and currently continuing the lipid angiogenic research as employee of CTI.
GROUP LEADER, ANALYTICAL LIPID BIOCHEMISTRY, CTI
1/95- present
Member of IND team to bring company’s lead product, Apra, to clinic. Group leader of lipid analysis responsible for elucidating the mechanism of action of the drug.
GROUP LEADER, LIPID ANGIOGENESIS, CTI 1/95- present
Managed collaborations with three separate research institutions performing in vitro and in vivo studies assaying the structure to function relationships of various lipid angiogenic molecules ($200,000 budget).
GROUP LEADER, METABOLITES OF LYSOFYLLINE, CTI
3/97-2/98
Led research and development leading to identification of novel
intellectual property defining the in vivo metabolites of one of the company’s lead compounds, Lisofylline.
MEMBER, PROJECT TEAM, OXIDIZED LIPIDS IN HUMAN SERUM, CTI
4/97-7/05
Developed proprietary extraction protocol and novel thin layer
chromatography (TLC) technology leading to a fascile and very
sensitve assay for the detection of oxidized lipids in human plasma.
PROGRAM HEAD, ZYMEQUEST CORPORATION
9/05-6/08
Organized, developed and implemented program for biochemical
analysis of surface lipids on rbc’s including all immunological assays
and state-of-art techniques.
HEAD SCIENTIST AND CO-FOUNDER, GLYCOZYM INC
6/08 to present
World-leader in tumor-markers and early diagnosis of cancer with a simple blood test.
Please view our website for details: http://www.glycozym.com/
*********
